Cingulate Inc. (CING)
4.29
0.13 (3.13%)
At close: Apr 23, 2025, 3:59 PM
4.25
-0.87%
Pre-market: Apr 24, 2025, 04:04 AM EDT
3.13% (1D)
| Bid | 4.2 |
| Market Cap | 16.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.24B |
| EPS (ttm) | -10.2 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -15.44 |
| Analyst | Buy |
| Ask | 4.38 |
| Volume | 93,252 |
| Avg. Volume (20D) | 109,996.5 |
| Open | 4.29 |
| Previous Close | 4.16 |
| Day's Range | 4.22 - 4.44 |
| 52-Week Range | 1.80 - 20.83 |
| Beta | -0.88 |
About CING
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety diso...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CING
Website https://www.cingulate.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CING stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 366.20% from the latest price.
Stock Forecasts3 days ago
-4.01%
Cingulate shares are trading lower after Ascendian...
Unlock content with
Pro Subscription
5 months ago
+9.27%
Cingulate shares are trading higher after Maxim Group upgraded the stock from Hold to Buy.
